Insilico, US partner to build AI models predicting disease decades ahead

🇭🇰 public Hong Kong · May 27, 2026 · 226 words · By Julie Zhang

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Insilico, US partner to build AI models predicting disease decades ahead

Insilico teams up with US firm to build AI models predicting disease decades ahead Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research The partnership was announced as the…

Claims checked 9

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center83%

Right17%

6 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

Insilico founder and CEO Alex Zhavoronkov, in a written reply, framed the tie-up as the world’s two leading companies in the AI and longevity fields joining forces, adding they “have developed a conceptually new type of personal longevity AI that will not…

Common ground

They described the arrangement as “a multimillion-dollar AI co-development collaboration”.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Insilico, US partner to build AI models predicting disease decades ahead?
What evidence would most clearly confirm or weaken the claim that the global longevity market... was valued at about US$5.3 trillion and projected to reach US$8 trillion by 2030, according to a recent UBS report?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.scmp.com/business/china-business/article/3354923/insilico-teams-us-f…

fact_checkClaims Checked

eFinder analyzed this article and checked 9 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 4

info Single Source 3

help Insufficient Evidence 1

verified Verified By Reference 1

info

Claim 1: “the global longevity market... was valued at about US$5.3 trillion and projected to reach US$8 trillion by 2030, according to a recent UBS report”

SINGLE SOURCE

While web results mention the '$8 Trillion Opportunity' in longevity, the specific attribution to a 'recent UBS report' regarding the $5.3 trillion current valuation is not explicitly corroborated by multiple independent sources in the provided evidence; only general articles about the market size are present.

menu_book

wikipedia NEUTRAL — The 2011 UBS rogue trader scandal caused a loss of over US$2 billion at Swiss bank UBS, as a result of unauthorized trading performed by Kweku Adoboli, a director of the bank's Global Synthetic Equiti…
https://en.wikipedia.org/wiki/2011_UBS_rogue_trader_scandal

menu_book

wikipedia NEUTRAL — UBS Group AG (stylized simply as UBS) is a Swiss multinational investment bank and financial services firm founded and based in Switzerland, with headquarters in both Zurich and Basel. It holds a stro…
https://en.wikipedia.org/wiki/UBS

menu_book

wikipedia NEUTRAL — UBS Arena is a multi-purpose indoor arena located in Elmont, New York, just outside New York City limits. Opened in 2021, it is the home of the New York Islanders of the National Hockey League (NHL), …
https://en.wikipedia.org/wiki/UBS_Arena

+ 3 more evidence sources

help

Claim 2: “The collaboration will be executed through Human Life Foundation Models (HLFM), a newly launched company set up by Human Longevity”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results to confirm the existence or role of 'Human Life Foundation Models (HLFM)'.

info

Claim 3: “Shares of Insilico declined 4.21 per cent to HK$48.28 apiece on Tuesday and slipped a further 0.4 per cent to HK$48.10 on Wednesday”

SINGLE SOURCE

The provided evidence for this claim consists of general company descriptions and a different deal with Eli Lilly; there is no specific data regarding stock price movements on Tuesday or Wednesday in the provided evidence.

travel_explore

web search NEUTRAL — Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, [3] with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of …
https://en.wikipedia.org/wiki/Insilico_Medicine

travel_explore

web search NEUTRAL — Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best — take large amounts of data from many components to identify new targets, and new molecules.
https://insilico.com/

travel_explore

web search NEUTRAL — Mar 29, 2026 · Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs. The two companies have worked together since 2023.
https://www.cnbc.com/2026/03/29/eli-lilly-reaches-deal-to-br…

check_circle

Claim 4: “They described the arrangement as “a multimillion-dollar AI co-development collaboration””

CORROBORATED

Multiple independent web search results explicitly use the phrase 'multimillion-dollar AI co-development collaboration' to describe the arrangement.

menu_book

wikipedia NEUTRAL — In the life extension movement, longevity escape velocity (LEV), actuarial escape velocity or biological escape velocity is a hypothetical situation in which one's remaining life expectancy (not life …
https://en.wikipedia.org/wiki/Longevity_escape_velocity

menu_book

wikipedia NEUTRAL — Alex Zhavoronkov (born Aleksandrs Zavoronkovs) is a Latvian-born scientist and author working in biotechnology, regenerative medicine, and aging economics. He is the founder and CEO of Insilico Medici…
https://en.wikipedia.org/wiki/Alex_Zhavoronkov

menu_book

wikipedia NEUTRAL — Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong…
https://en.wikipedia.org/wiki/Insilico_Medicine

+ 3 more evidence sources

check_circle

Claim 5: “Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data”

CORROBORATED

Web search results confirm the partnership between Insilico Medicine and Human Longevity to combine algorithms with genomic data. Additionally, multiple sources (including Bloomberg and Eli Lilly deal reports) refer to Insilico as 'Hong Kong-listed'.

menu_book

wikipedia NEUTRAL — XtalPi Holdings Limited (XtalPi; Chinese: 晶泰科技; pinyin: Jīngtài Kējì) is a publicly listed Chinese biotechnology company that engages in research and development for early-stage drug discovery and mat…
https://en.wikipedia.org/wiki/XtalPi

+ 3 more evidence sources

check_circle

Claim 6: “Its self-developed AI platform spans the entire drug discovery process, from identifying disease targets to designing drug candidates and predicting clinical outcomes”

CORROBORATED

Multiple sources describe Insilico's 'full-stack' AI approach covering target identification, drug candidate generation, and outcome prediction.

travel_explore

web search NEUTRAL — Dec 16, 2025 · Adaptive Trial Design and Outcome Prediction: AI can facilitate the design of adaptive clinical trials, where parameters such as dosage or ...
https://www.drugpatentwatch.com/blog/the-ai-revolution-in-dr…

travel_explore

web search NEUTRAL — Using this “toolkit,” Insilico seeks to both discover first-in-class targets and generate drug candidates against them, a “full-stack” AI approach. The ...
https://www.sciencedirect.com/science/article/abs/pii/S00316…

travel_explore

web search NEUTRAL — This allows for the discovery of novel therapeutic targets and for the prediction of potential drug candidates with better accuracy and at a faster pace than ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC11510778/

verified

Claim 7: “Alex Zhavoronkov is Insilico founder and CEO”

VERIFIED BY REFERENCE

Confirmed by Wikipedia and multiple other authoritative sources (CNBC, CXOTalk, XPRIZE) that Alex Zhavoronkov is the founder and CEO of Insilico Medicine.

menu_book

wikipedia NEUTRAL — The SENS Research Foundation is a non-profit organization that does research programs and public relations work for the application of regenerative medicine to aging. It was founded in 2009, located i…
https://en.wikipedia.org/wiki/SENS_Research_Foundation

menu_book

wikipedia NEUTRAL — Zhavoronkov is a Russian surname. People with the surname include: Alex Zhavoronkov (fl. 2010s–2020s), CEO of Insilico Medicine Semyon Zhavoronkov (1899–1967), Soviet naval officer Sergey Zhavoronkov…
https://en.wikipedia.org/wiki/Zhavoronkov

+ 4 more evidence sources

check_circle

Claim 8: “Insilico teams up with US firm to build AI models predicting disease decades ahead”

CORROBORATED

Multiple independent web search results confirm that Insilico Medicine has partnered with a US firm (Human Longevity) to build AI models for predicting diseases decades in advance.

menu_book

wikipedia NEUTRAL — Rentosertib (also known as ISM001‑055 and INS018_055) is an investigational new drug that is being evaluated for the treatment of idiopathic pulmonary fibrosis (IPF). It targets TNIK (TRAF2 and NCK-i…
https://en.wikipedia.org/wiki/Rentosertib

menu_book

+ 3 more evidence sources

info

Claim 9: “The company raised HK$2.28 billion (US$291 million) in its initial public offering in December”

SINGLE SOURCE

One source (Bamboo) mentions the Dec 30 listing and pricing, but the specific figure of HK$2.28 billion raised is not corroborated by a second independent source in the provided evidence.

travel_explore

web search NEUTRAL — Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts,[3] with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of H…
https://en.wikipedia.org/wiki/Insilico_Medicine

travel_explore

web search NEUTRAL — Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research.
https://www.scmp.com/business/china-business/article/3354923…

travel_explore

web search NEUTRAL — The deal offers further cause for investor cheer after InSilico’s Dec. 30 main-board listing, priced at HK$24.05 per share, which was oversubscribed more than 1400 times and locked in more than HK$328…
https://thebambooworks.com/insilico-lands-drug-discovery-dea…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.